Skip to main content
logo
Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
16.38
+1.51 (10.15%)
At close: Aug 4, 2026, 4:00 PM EDT
15.84
-0.54 (-3.30%)
Pre-market: Aug 5, 2026, 6:55 AM EDT

Crescent Biopharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-10.84-0.010.081.16
Revenue Growth
----86.67%-93.53%-88.59%
Gross Profit
-10.84-0.010.081.16
Operating Income
-168.47-152.63-40.04-39.28-47.4-63.45
Net Income
-165.12-153.94-37.88-36.9-46.69-63.43
Earnings Per Share
-6.72-12.81-59.00-58.00-89.00-123.00
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
171.59213.1934.7741.7947.8790.25
Total Debt
1.441.6437.480.740.921
Net Cash (Debt)
170.16211.55-2.7241.0546.9589.25
Net Cash Growth
11.63%---12.57%-47.39%-34.44%
Net Cash Per Share
6.9720.31-4.2164.8189.38173.47

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-72.68-71.53-6.27-34.88-46.46-57.49
Capital Expenditures
-0.94-0.92--0.02-0.08-0.01
Free Cash Flow
-73.62-72.45-6.27-34.9-46.54-57.5
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-100.00%-100.00%100.00%100.00%
Operating Margin
--1407.52%--392753.00%-63204.40%-5470.69%
Pretax Margin
--1401.16%--345235.47%-62251.74%-5468.98%
Profit Margin
--1419.61%--368994.00%-62251.70%-5468.98%
FCF Margin
--668.12%--349013.00%-62055.60%-4958.28%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
59.0033.30-15196.902196.8664.95